News

A supervised walking program, practiced three times a week for 16 weeks, safely improves cardiorespiratory fitness and exercise capacity while reducing fatigue in women with primary Sjögren’s syndrome, a clinical study found. The study, “Supervised walking improves cardiorespiratory…

The PI3K-delta inhibitor known as seletalisib, an investigative treatment for primary Sjögren’s syndrome, improved the production of saliva, lowered the levels of autoantibodies and inflammatory mediators, and decreased immune B- and T-cell infiltration in salivary glands in a mouse model, study researchers report. The study, “Phosphatidylinositol 3-kinase delta…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Patients with primary Sjogren’s syndrome (pSS) and systemic lupus erythematosus (SLE) share their gut microbial composition, which is different from the general population. Oral microbial composition, however, in different in both patient groups. The research, “Shared gut, but distinct oral microbiota composition in primary Sjögren’s syndrome…

A combination of leflunomide and hydroxychloroquine significantly reduced disease activity, increased salivary flow, and improved patient-perceived health in patients with primary Sjögren’s syndrome, a pilot trial showed. Findings of the trial were revealed at the recent American College of Rheumatology 2018 Meeting, in Chicago. Timothy Radstake, MD, PhD, from the …